Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Exagen Inc.NASDAQ: XGN

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $655K rose 57.1% year over year, ahead of the +47.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at -22.9% a year.

Context

  • Stock-based compensation amounted to 3.2% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +57.1% holds above the trailing-twelve-month pace of +47.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$655K-7.1% QoQ
Last fiscal yearDec 2025
$2.16M+22.4% YoY
LTMMar 2026
$2.4M+47.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.1%——
1 year+22.4%——
3-year CAGR-22.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.16M USD
Year-over-year change
+22.4%
4-year CAGR
-17.8%

Stock-Based Compensation vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 stock-based compensation of $2.4M is the 9th largest of the 11 companies compared; the peer median is $9.25M.
  • Its year-over-year change of +47.3% is the highest of 10, against a peer median of -7.7%.
  • Stock-based compensation amounts to 3.5% of revenue for XGN, versus a peer median of 5.1%.
XGN Competitors Peer median
Stock-Based Compensation for XGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
BIOABioAge Labs, Inc.LTM Mar 2026$13M +43.2%+66.3%126.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M -2.1%-6.3%144.0%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M -30.6%+0.2%14.7%
STXSStereotaxis, Inc.LTM Mar 2026$9.43M -7.7%-2.3%30.2%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$9.07M -23.3%-16.5%4.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.91M —+57.3%4.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.42M +1.9%-2.6%5.8%
XGNExagen Inc.LTM Mar 2026$2.4M +47.3%-22.9%3.5%
MDXHMDxHealth S.A.FY2025$2.21M +28.2%+36.6%2.0%
SMTISanara MedTech Inc.LTM Mar 2026$442.14K -91.0%-35.7%0.4%
Peer median (excluding XGN) $9.25M-7.7%-1.1%5.1%

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
Deferred Income Tax148K(306K)000
Stock-Based Compensation4.73M4.7M3.62M1.76M2.16M
Change in Working Capital(61K)1.67M325K(3.08M)(1.98M)
Accounts Receivables(744K)3.58M(474K)(1.28M)(3.02M)
Inventory00000
Accounts Payables(655K)901K67K308K42K
Other Working Capital1.34M(2.81M)732K(2.1M)997K
Other Non-Cash Items819K7.62M3.12M1.43M4.03M
Operating Cash Flow(20.27M)(32.14M)(14.46M)(13.28M)(13.63M)
Capital Expenditures(2.37M)(4.32M)(828K)(515K)(641K)
Acquisitions (Net)000015K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(50K)024K00
Investing Cash Flow(2.42M)(4.32M)(804K)(515K)(626K)
Debt Repayment(525K)(696K)(10.94M)(861K)2.01M
Common Stock Issued69.14M446K306K198K22.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.94M)(239K)000
Financing Cash Flow64.68M(489K)(10.63M)(663K)24.44M
Effect of Forex Changes00000
Net Change in Cash41.99M(36.95M)(25.9M)(14.46M)10.18M
Free Cash Flow(22.64M)(36.46M)(15.29M)(13.79M)(14.27M)

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.